Drug intelligence / Profile preview

NMDP-04

Development stage: Preclinical
Lead developer: NMD Pharma
Modality: Small Molecules
Administration: Oral

Overview

NMDP-04 is a preclinical-stage small molecule inhibitor of the skeletal muscle-specific chloride channel ClC-1, currently under development by NMD Pharma. The ClC-1 channel is primarily responsible for maintaining the resting membrane conductance of skeletal muscle fibers; its inhibition increases the excitability of the muscle fiber membrane. This mechanism is designed to compensate for impaired neuromuscular transmission, thereby improving muscle strength and reducing fatigue. NMDP-04 is being investigated for the treatment of rare neuromuscular diseases where muscle excitability is compromised.

Targets

CLCN1 (CLC-1)

Beyond the preview

Go deeper on NMDP-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMDP-04.

Explore the full profile